The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary

Once daily abacavir?

Jan 30, 2007

Firstly, thank you for your fantastic work! Seondly, my partner has been on meds successfully for five years, and his doctor has just reccommended a switch from AZT, Sustiva and Abacavir, by replacing the AZT with Viread, to prevent long-term toxicity. As the Sustiva and Viread are once daily tablets, the doctor has recommended that my partner also take both abacavir pills at the same time, creating a once daily regimen. What is the evidence that abacavir is successful on a once-daily basis, and would you recommend it? My partner has an undetectable viral load, and CD4 of usually between 600-800

Response from Dr. Young

Thanks for your post.

Abacavir (Ziagen, part of Epzicom and Trizivir) has long been US FDA and European agency approved as a once-daily medication. There are several large, prospective randomized studies that show that once- and twice-daily abacavir are functionally equivalent. BY

what about getting a tattoo?
Understanding Lifespan

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint